Immunosuppressants - Americas

Americas

In the Americas region, the Immunosuppressants market is expected to witness substantial growth in the coming years.
According to projections, the market's revenue is set to reach US$37.64bn in 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate (CAGR 2024-2029) of 14.89%.
This growth trajectory is expected to result in a market volume of US$75.35bn by 2029.
When compared globally, United States is forecasted to generate the highest revenue in the Immunosuppressants market.
Specifically, it is estimated that United States will generate US$35,470.00m in revenue in 2024.
This highlights the significant market presence and potential of the United States within the Immunosuppressants market.
In the Americas, the market for immunosuppressants is experiencing a significant increase due to the rising prevalence of autoimmune diseases in the region.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Americas has been experiencing significant growth in recent years, driven by a range of factors including an increase in the number of organ transplants, rising prevalence of autoimmune diseases, and growing demand for immunosuppressant drugs.

Customer preferences: Patients and healthcare providers in the Americas region are increasingly turning to immunosuppressant drugs to manage a range of conditions, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Additionally, with an aging population and an increasing number of organ transplants, the demand for immunosuppressant drugs is expected to continue to rise in the coming years.

Trends in the market: In the United States, the largest market for immunosuppressant drugs in the Americas, the market has been driven by the approval of new drugs and the increasing use of combination therapies. Additionally, the market has seen a shift towards the use of biologic drugs over traditional immunosuppressants, as these drugs offer more targeted and effective treatments with fewer side effects.In Canada, the market for immunosuppressants has been driven by the increasing prevalence of autoimmune diseases, particularly among women. The market has also been impacted by the rising cost of these drugs, which has led to increased pressure on healthcare budgets and a greater focus on cost-effective treatment options.In Latin America, the market for immunosuppressants has been growing rapidly, driven by an increase in the number of organ transplants and a rising prevalence of autoimmune diseases. However, the market is also highly fragmented, with a range of local and regional players competing with multinational pharmaceutical companies.

Local special circumstances: In Brazil, the largest market in Latin America, the government has implemented a range of policies to increase access to immunosuppressant drugs for patients. This has included the provision of free or subsidized drugs for low-income patients, as well as the establishment of a national registry for organ transplants to improve the allocation of donor organs.In Mexico, the market for immunosuppressants has been impacted by a range of factors, including the high cost of drugs, limited access to healthcare services in rural areas, and a lack of public awareness of the importance of organ donation.

Underlying macroeconomic factors: The growth of the immunosuppressants market in the Americas is also being driven by a range of underlying macroeconomic factors, including increasing healthcare spending, rising disposable incomes, and a growing awareness of the importance of preventative healthcare. Additionally, the market is being impacted by changing demographics, with an aging population driving demand for treatments for chronic conditions such as autoimmune diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.